´ëÇÑ°£ÇÐȸ APASL STC 2023 DAY 2 : 2023-09-22
±³À°ÀÏÀÚ : 2023-09-22
±³À°Àå¼Ò : ºÎ»ê º¤½ºÄÚ ROOM 1~4
±³À°ÁÖÁ¦ : APASL STC 2023 DAY 2
ÁÖÃÖ±â°ü : ´ëÇÑ°£ÇÐȸ
´ã´çÀÚ : APASL STC Áغñ»ç¹«±¹
¿¬¶ôó : 02-373-1005
À̸ÞÀÏ : apaslstc2023@hbni.co.kr
±³À°Á¾·ù : ³»°ú
Âü¼®¿¹»óÀÎ : 1000¸í
Èñ¸ÁÆòÁ¡ : 6Á¡
Áö¿ª : ºÎ»ê±¤¿ª½Ã
±³À°½Ã°£ : 19 ½Ã°£ 10ºÐ
¼¼ºÎ¼ö°·á : 320,000¿ø
ºñ°í Early Bird Registration-APASL Member USD 100/Non-Member USD 150/Trainee / Resident / Researcher / Nurse USD 50/Abstract Presenting Author USD 50/Group (more than 10)USD 50 Regular Registration-APASL Member USD 150/Non-Member USD 200/Trainee / Resident / Researcher / Nurse USD 80/Abstract Presenting Author USD 50/Group (more than 10)USD 80
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 09¿ù 22ÀÏ ROOM 1 08:30~08:50 Ultra-High Sensitivity HBsAg and Anti-HBc in Managing Chronic Hepatitis B Jihyun An(Hanyang Univ., Korea)
±³À°½Ã°£ 09¿ù 22ÀÏ ROOM 1 08:50~09:10 HBcrAg and HBV RNA in Managing Chronic Hepatitis B Lung Yi Mak(The Univ. of Hong Kong, Hong Kong)
±³À°½Ã°£ 09¿ù 22ÀÏ ROOM 1 09:10~09:30 Circulating Virus-Host Chimera DNAs for Monitoring Virus-Related HCC Shiou-Hwei Yeh(National Taiwan Univ., Taiwan)
±³À°½Ã°£ 09¿ù 22ÀÏ ROOM 1 10:50~11:05 How to Manage Patients with Previous DAA Treatment Failure Young-Joo Jin(Inha Univ., Korea)
±³À°½Ã°£ 09¿ù 22ÀÏ ROOM 1 11:05~11:20 How to Manage Difficult-to-Cure Patients: Decompensated Disease and Transplantation In Hee Kim(Chonbuk National Univ., Korea)
±³À°½Ã°£ 09¿ù 22ÀÏ ROOM 1 11:20~11:35 Managing Drug-Drug Interaction, Adherence, and Adverse Events in the Era of Pangenotypic DAA Woo Jin Chung(Keimyung Univ., Korea)
±³À°½Ã°£ 09¿ù 22ÀÏ ROOM 1 11:35~11:50 Multidisciplinary Approach to Predict Fibrosis Progression and HCC after DAA Therapy Tawesak Tanwandee(Mahidol Univ., Thailand)
±³À°½Ã°£ 09¿ù 22ÀÏ ROOM 1 12:50~13:20 The Road to Curing Hepatitis B Virus Infection: Past, Present, and Future George Lau(Humanity and Health Medical Group, Hong Kong)
±³À°½Ã°£ 09¿ù 22ÀÏ ROOM 1 13:20~13:40 Genetic Polymorphism (& Family History) as a Non-Modifiable Risk Factor for HCC after HBV Cure Yoon Jun Kim(Seoul National Univ., Korea)
±³À°½Ã°£ 09¿ù 22ÀÏ ROOM 1 13:40~14:00 Viral Persistence after a Functional Cure of HBV and HCC Risk Jia-Horng Kao(National Taiwan Univ., Taiwan)
±³À°½Ã°£ 09¿ù 22ÀÏ ROOM 1 14:00~14:20 Molecular Mechanism of Hepatocarcinogenesis after SVR in Patients with HCV Raymond T. Chung(Harvard Univ. USA)
±³À°½Ã°£ 09¿ù 22ÀÏ ROOM 1 14:40~15:00 Classification and Clinical Characteristics of Gray Zone in Chronic Hepatitis B Marc G. Ghany(NIH, USA)
±³À°½Ã°£ 09¿ù 22ÀÏ ROOM 1 15:00~15:20 HBeAg-Positive "Gray-Zone": Should We Treat and Why? Tai-Chung Tseng(National Taiwan Univ., Taiwan)
±³À°½Ã°£ 09¿ù 22ÀÏ ROOM 1 15:20~15:40 HBeAg-Negative "Gray-Zone": Should We Treat and Why? Jordan Feld (Univ. of Toronto, Canada)
±³À°½Ã°£ 09¿ù 22ÀÏ ROOM 1 15:40~16:00 Optimizing Non-Invasive Methods to Identify Gray-Zone Patients with Liver Fibrosis Seung Up Kim(Yonsei Univ., Korea)
±³À°½Ã°£ 09¿ù 22ÀÏ ROOM 1 16:20~16:35 Stopping Antivirals Wen-Juei Jeng(Chang Gung Univ., Taiwan)
±³À°½Ã°£ 09¿ù 22ÀÏ ROOM 1 16:35~16:50 Continuing Antivirals Jonggi Choi(Ulsan Univ., Korea)
±³À°½Ã°£ 09¿ù 22ÀÏ ROOM 1 16:50~17:05 Interferon or Interferon-Based Therapy Tarik Asselah(Hepatology at Hôpital Beaujon, France)
±³À°½Ã°£ 09¿ù 22ÀÏ ROOM 1 17:05~17:20 Newer Antiviral Agents Robert Gish(The Univ. of Nevada, USA)
Åä·Ð 09¿ù 22ÀÏ ROOM 1 17:20~17:40 Panel Discussion ()
±³À°½Ã°£ 09¿ù 22ÀÏ ROOM 2 08:30~08:45 Liver and Spleen Stiffness for the Estimation of Portal Hypertension and Cirrhotic Complications Moonyoung Kim(Yonsei Univ. Wonju, Korea)
±³À°½Ã°£ 09¿ù 22ÀÏ ROOM 2 08:45~09:00 Antiviral Therapy and the Outcome of Patients with Decompensated Cirrhosis Sung Eun Kim(Hallym Univ., Korea)
±³À°½Ã°£ 09¿ù 22ÀÏ ROOM 2 09:00~09:15 Optimal Assessment and Improving Survival in Acute Variceal Bleeding Shiv Kumar Sarin(Institute of Liver & Biliary Sciences, India)
±³À°½Ã°£ 09¿ù 22ÀÏ ROOM 2 09:15~09:30 The Role of Antibiotic Therapy in Acute Decompensation Jung Gil Park(Yeungnam Univ., Korea)
±³À°½Ã°£ 09¿ù 22ÀÏ ROOM 2 09:30~09:45 Immunopathogenesis of Acute Hepatitis A Eui-Cheol Shin(KAIST, Korea)
±³À°½Ã°£ 09¿ù 22ÀÏ ROOM 2 09:45~10:00 Novel Therapies for Hepatitis Delta (HDV) Young Eun Chon(CHA Univ., Korea)
±³À°½Ã°£ 09¿ù 22ÀÏ ROOM 2 10:00~10:15 Disease Burden and Potential Therapeutic Approach to HEV Infection Lubna Kamani Liaquat(National Hospital, Pakistan)
±³À°½Ã°£ 09¿ù 22ÀÏ ROOM 2 10:15~10:30 Pathogenesis and Management of Non-Hepatotropic Viruses Ju-Yeon Cho (Chosun Univ., Korea)
±³À°½Ã°£ 09¿ù 22ÀÏ ROOM 2 10:50~11:05 Role of Metabolic Risk Factors in the Outcome of Viral Hepatitis Lai Wei(Tsinghua Univ., China)
±³À°½Ã°£ 09¿ù 22ÀÏ ROOM 2 11:05~11:20 Effects of Alcohol Drinking on the Prognosis of Patients with Viral Hepatitis Won Kim (Seoul National Univ., Korea)
±³À°½Ã°£ 09¿ù 22ÀÏ ROOM 2 11:20~11:35 MAFLD in Chronic Hepatitis B: Friend or Foe? Lung Yi Mak (The Univ. of Hong Kong, Hong Kong)
±³À°½Ã°£ 09¿ù 22ÀÏ ROOM 2 11:35~11:50 Management Strategies for Viral Hepatitis with Concurrent MAFLD Hye Won Lee (Yonsei Univ., Korea)
±³À°½Ã°£ 09¿ù 22ÀÏ ROOM 2 14:40~15:00 Anti-HBV Therapy to Prevent HBV-Associated HCC Tetsuya Hosaka(Toranomon Hospital, Japan)
±³À°½Ã°£ 09¿ù 22ÀÏ ROOM 2 15:00~15:20 Anti-HCV Therapy to Prevent HCV-Associated HCC Do Young Kim(Yonsei Univ., Korea)
±³À°½Ã°£ 09¿ù 22ÀÏ ROOM 2 15:20~15:40 Non-Viral Managements to Prevent HCC Dong Hyun Sinn (Sungkyunkwan Univ., Korea)
±³À°½Ã°£ 09¿ù 22ÀÏ ROOM 2 15:40~16:00 (Cost-Effective) Risk-Stratified Surveillance for Hepatitis Virus-Associated HCC Shuichiro Shiina(Juntendo Univ., Japan)
±³À°½Ã°£ 09¿ù 22ÀÏ ROOM 2 16:20~16:40 Developing AI Model for Predicting HCC Hwi Young Kim(Ewha Womans Univ., Korea)
±³À°½Ã°£ 09¿ù 22ÀÏ ROOM 2 16:40~17:00 Radiomics and Deep Learning for Chronic Liver Disease Roongruedee Chaiteerakij(Chulalongkorn Univ., Thailand)
±³À°½Ã°£ 09¿ù 22ÀÏ ROOM 2 17:00~17:20 Harnessing Knowledge and Experimental Data Using AI Drug Discovery Technology Han Jo Kim(Standigm, Korea)
±³À°½Ã°£ 09¿ù 22ÀÏ ROOM 2 17:20~17:40 Deep Learning-Based Prediction of Biomarkers Using Liver Cancer Histopathological Images Sung Hak Lee(The Catholic Univ. of Korea, Korea)
±³À°½Ã°£ 09¿ù 22ÀÏ ROOM 3 07:30~07:42 Impact of Metabolic Factors on the Risk of HBV-Related HCC Yun Bin Lee(Seoul National Univ., Korea)
±³À°½Ã°£ 09¿ù 22ÀÏ ROOM 3 07:42~07:54 Have Risk Factors for HCC Changed over the Decades? Roongruedee Chaiteerakij (Chulalongkorn Univ., Thailand))
Åä·Ð 09¿ù 22ÀÏ ROOM 3 07:54~08:20 Discussion ()
±³À°½Ã°£ 09¿ù 22ÀÏ ROOM 3 09:30~09:50 HBV cccDNA: Mechanism of Its Formation and Therapeutic Targets Kyun-Hwan Kim(Sungkyunkwan Univ., Korea)
±³À°½Ã°£ 09¿ù 22ÀÏ ROOM 3 09:50~10:10 HBV Integration and Liver Cancer Thomas Tu(Univ. of Sydney, Australia)
±³À°½Ã°£ 09¿ù 22ÀÏ ROOM 3 10:10~10:30 Genome Editing for cccDNA and Integrated HBV Jae Young Lee(ToolGen, Korea)
±³À°½Ã°£ 09¿ù 22ÀÏ ROOM 3 10:50~11:05 Type I and III IFN Responses in Hepatitis Virus Infection Pil Soo Sung(The Catholic Univ. of Korea, Korea)
±³À°½Ã°£ 09¿ù 22ÀÏ ROOM 3 11:05~11:20 T-Cell Responses and Immunopathogenesis of Viral Hepatitis Yuri Cho(National Cancer Center, Korea)
±³À°½Ã°£ 09¿ù 22ÀÏ ROOM 3 11:20~11:35 Characteristics of B Cells in HBV-Infected Liver Ji Eun Oh(KAIST, Korea)
±³À°½Ã°£ 09¿ù 22ÀÏ ROOM 3 11:35~11:50 Chronic Hepatitis and Liver Fibrosis in Humans Hideki Ueno (Kyoto Univ., Japan)
±³À°½Ã°£ 09¿ù 22ÀÏ ROOM 3 13:20~13:35 Treatment of Chronic Hepatitis B: When and Whom? Jae Yoon Jeong (National Medical Center, Korea)
±³À°½Ã°£ 09¿ù 22ÀÏ ROOM 3 13:35~13:50 Diagnosis and Management of Hepatitis C Virus Infection Yun Chin Cho(Gyeongsang National Univ., Korea)
±³À°½Ã°£ 09¿ù 22ÀÏ ROOM 3 13:50~14:05 Diagnosis and Management of Autoimmune Hepatitis Young Chang(Soonchunhyang Univ., Korea)
±³À°½Ã°£ 09¿ù 22ÀÏ ROOM 3 14:05~14:20 Surveillance and Diagnosis of HCC Han Ah Lee(Ewha Womans Univ., Korea)
±³À°½Ã°£ 09¿ù 22ÀÏ ROOM 3 14:40~15:00 Epidemiology, Natural History and Risk Stratification of NAFLD Yang Hyon Baek(Dong-A Univ., Korea)
±³À°½Ã°£ 09¿ù 22ÀÏ ROOM 3 15:00~15:20 Lifestyle Intervention and Available Medications in NAFLD Treatment Se Young Jang(Kyungpook National Univ., Korea)
±³À°½Ã°£ 09¿ù 22ÀÏ ROOM 3 15:20~15:40 Management of Severe Alcoholic Hepatitis Tae Suk Kim (Kangwon National Univ., Korea)
±³À°½Ã°£ 09¿ù 22ÀÏ ROOM 3 15:40~16:00 Updated Guideline on Drug-Induced Liver Injury Nae-Yun Heo (Inje Univ., Korea)
±³À°½Ã°£ 09¿ù 22ÀÏ ROOM 3 16:20~16:40 Diagnosis and Management of Ascites and Related Complications Chang Hun Lee(Jeonbuk National Univ., Korea)
±³À°½Ã°£ 09¿ù 22ÀÏ ROOM 3 16:40~17:00 Diagnosis and Management of Acute Variceal Bleeding Seong Hee Kang(Korea Univ., Korea)
±³À°½Ã°£ 09¿ù 22ÀÏ ROOM 3 17:00~17:20 When Is the Appropriate Time for Liver Transplantation? Kwang Il Seo(Kosin Univ., Korea)
±³À°½Ã°£ 09¿ù 22ÀÏ ROOM 3 17:20~17:40 Treatment strategy based on HCC stage Jung Hwan Yu (Inha Univ., Korea)
±³À°½Ã°£ 09¿ù 22ÀÏ ROOM 4 07:30~07:42 Does Metabolic Derangement Corrected after Cure of HCV? Eun Ju Cho(Seoul National Univ., Korea)
±³À°½Ã°£ 09¿ù 22ÀÏ ROOM 4 07:42~07:54 Effects of DAA Treatment on Extrahepatic Manifestations in HCV Infection Hyun Phil Shin(Kyung Hee Univ., Korea)
Åä·Ð 09¿ù 22ÀÏ ROOM 4 07:54~08:20 Discussion Geum-Youn Gwak(Sungkyunkwan Univ., Korea)